SK Bioscience reported third-quarter revenue of 182.4 billion won and an operating loss of 11.2 billion won. Revenue rose 21% from 150.8 billion won a year earlier, while the operating loss narrowed 42%. Despite the improvement, the company remained in the red for the 11th consecutive quarter, extending a run that began in the fourth quarter of 2023.

Revenue improves while losses continue

The company said the latest loss was the smallest during that period. SK Bioscience entered a loss-making phase after the pandemic ended, as sales of its own COVID-19 vaccine Skycovione no longer provided the growth seen during the pandemic. Costs from moving its headquarters to Songdo, Incheon, and increased research and development spending for future businesses also weighed on this year’s results.

Through the first three quarters, the company accumulated an operating loss of 71.5 billion won. That is below the 123.5 billion won loss recorded for all of the previous year, and the company expects further year-on-year improvement. The figures show narrower losses, but they do not yet mark a return to operating profit.

The strongest improvement came from IDT Biologika, acquired in 2024. IDT posted third-quarter revenue of 113.1 billion won, up 21% year on year, and operating profit of 9.6 billion won, up about 66%. SK Bioscience attributed the gains to higher production volumes for major customers, a larger share of high-margin sales, and more efficient production and operations. The company plans to use IDT, its own and partnered vaccine sales, expanded next-generation vaccine pipelines, and overseas markets as growth pillars.